Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study
Annals of Gastroenterology · 2024
DOI: 10.20524/aog.2024.0897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Gastroenterology, 2024. Verfasst von Apostolis Papaefthymiou und 33 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases and Surgery institute, Cleveland Clinic, London, UK (Apostolis Papaefthymiou, Alberto Murino, Benjamin Norton, Andrea Telese, Reha…. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Hemostatic powders are used as second-line treatment in acute gastrointestinal (GI) bleeding (AGIB). Increasing evidence supports the use of TC-325 as monotherapy in specific scenarios. This prospective, multicenter study evaluated the performance of TC-325 as monotherapy for AGIB.
Methods
Eighteen centers across Europe and USA contributed to a registry between 2016 and 2022. Adults with AGIB were eligible, unless TC-325 was part of combined hemostasis. The primary endpoint was immediate hemostasis. Secondary outcomes were rebleeding and mortality. Associations with risk factors were investigated (statistical significance at P≤0.05).
Results
One hundred ninety patients were included (age 51-81 years, male: female 2:1), with peptic ulcer (n=48), upper GI malignancy (n=79), post-endoscopic treatment hemorrhage (n=37), and lower GI lesions (n=26). The primary outcome was recorded in 96.3% (95% confidence interval [CI]: 92.6-98.5) with rebleeding in 17.4% (95%CI 11.9-24.1); 9.9% (95%CI 5.8-15.6) died within 7 days, and 21.7% (95%CI 15.6-28.9) within 30 days. Regarding peptic ulcer, immediate hemostasis was achieved in 88% (95%CI 75-95), while 26% (95%CI 13-43) rebled. Higher ASA score was associated with mortality (OR 23.5, 95%CI 1.60-345; P=0.02). Immediate hemostasis was achieved in 100% of cases with malignancy and post-intervention bleeding, with rebleeding in 17% and 3.1%, respectively. Twenty-six patients received TC-325 for lower GI bleeding, and in all but one the primary outcome was achieved.
Conclusions
TC-325 monotherapy is safe and effective, especially in malignancy or post-endoscopic intervention bleeding. In patients with peptic ulcer, it could be helpful when the primary treatment is unfeasible, as bridge to definite therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digestive Diseases and Surgery institute, Cleveland Clinic, London, UK (Apostolis Papaefthymiou, Alberto Murino, Benjamin Norton, Andrea Telese, Rehan Haidry).
- Department of Gastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK (Nasar Aslam, Rehan Haidry).
- Division of Surgery and Interventional Sciences, University College London, UK (Mohamed Hussein, Durayd Alzoubaidi, Andrea Telese, Rehan Haidry).
- Department of Gastroenterology and Hepatology, Guy's and St Thomas' NHS Foundation Trust, UK (Mohamed Hussein).
- NYU Langone, New York, USA (Seth A. Gross, Melissa Latorre, Michael O'Donnell).
- Department of Gastroenterology and Hepatology, Ramon y Cajal University Hospital, IRYCIS, CIBEREHD, University of Alcala, Madrid, Spain (Alvaro De La Serna, Enrique Rodríguez De Santiago).
Zitieren
APA
Papaefthymiou, A., Aslam, N., Hussein, M., Alzoubaidi, D., Gross, S. A., Serna, A., Varbobitis, I., Hengehold, T. A., López, M. F., Fernández-Sordo, J. O., Rey, J. W., Hayee, B., Despott, E. J., Murino, A., Moreea, S., Boger, P., Dunn, J. M., Mainie, I., Mullady, D., …, & Haidry, R. (2024). Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study. Annals of Gastroenterology. https://doi.org/10.20524/aog.2024.0897
Vancouver
Papaefthymiou A, Aslam N, Hussein M, Alzoubaidi D, Gross SA, Serna A, et al. Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study. Annals of Gastroenterology. 2024. doi:10.20524/aog.2024.0897
BibTeX
@article{Papaefthymiou2024,
author = {Papaefthymiou, Apostolis and Aslam, Nasar and Hussein, Mohamed and Alzoubaidi, Durayd and Gross, Seth A and Serna, Alvaro De La and Varbobitis, Ioannis and Hengehold, Tricia A and López, Miguel Fraile and Fernández-Sordo, Jacobo Ortiz and Rey, Johannes W and Hayee, Bu and Despott, Edward J and Murino, Alberto and Moreea, Sulleman and Boger, Phil and Dunn, Jason M and Mainie, Inder and Mullady, Daniel and Early, Dayna and Latorre, Melissa and Ragunath, Krish and Anderson, John T and Bhandari, Pradeep and Goetz, Martin and Kiesslich, Ralf and Coron, Emmanuel and Santiago, Enrique Rodríguez De and Gonda, Tamas A and O'Donnell, Michael and Norton, Benjamin and Telese, Andrea and Simons-Linares, Roberto and Haidry, Rehan},
title = {Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study},
journal = {Annals of Gastroenterology},
year = {2024},
doi = {10.20524/aog.2024.0897}
}
EUVIMED